Hepalink Pharmaceutical Co., Ltd. will acquire Scientific Protein Laboratories, LLC. (SPL), a global API manufacturer, for $337.5 million in cash, plus contingent payments. According to a Hepalink statement, the acquisition will enable the company to expand its presence in the heparin supply market, while providing it with greater product development and growth opportunities in new markets for its line of APIs, including pancreatic enzyme and heparin products.    Hepalink plans to keep SPL’s...